CytomX Therapeutics Inc CTMX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CTMX is a good fit for your portfolio.
News
-
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
-
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
-
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
-
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
-
Stocks to Watch: Oracle, Mission Produce, CytomX Therapeutics
-
CytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing Candidate
-
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
-
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
Trading Information
- Previous Close Price
- $1.63
- Day Range
- $1.58–1.64
- 52-Week Range
- $1.04–2.86
- Bid/Ask
- $1.60 / $1.61
- Market Cap
- $108.37 Mil
- Volume/Avg
- 286,315 / 996,973
Key Statistics
- Price/Earnings (Normalized)
- 17.03
- Price/Sales
- 1.26
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 122
- Website
- https://www.cytomx.com
Comparables
Valuation
|
Metric
|
CTMX
|
AURA
|
CGEM
|
|---|---|---|---|
Price/Earnings (Normalized) | 17.03 | — | — |
Price/Book Value | — | 1.55 | 1.79 |
Price/Sales | 1.26 | — | — |
Price/Cash Flow | 19.72 | — | — |
Price/Earnings
CTMX
AURA
CGEM
Financial Strength
|
Metric
|
CTMX
|
AURA
|
CGEM
|
|---|---|---|---|
Quick Ratio | 1.14 | 18.30 | 16.60 |
Current Ratio | 1.17 | 18.76 | 17.07 |
Interest Coverage | — | — | — |
Quick Ratio
CTMX
AURA
CGEM
Profitability
|
Metric
|
CTMX
|
AURA
|
CGEM
|
|---|---|---|---|
Return on Assets (Normalized) | 2.75% | −32.93% | −24.60% |
Return on Equity (Normalized) | — | −37.86% | −25.95% |
Return on Invested Capital (Normalized) | — | −37.41% | −29.67% |
Return on Assets
CTMX
AURA
CGEM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nnbzsdmkd | Qmxrw | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jjqjtnnk | Yzlwxtj | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Znrvwxw | Dbhbqx | $99.5 Bil | |
MRNA
| Moderna Inc | Xkfvjlv | Qymn | $38.8 Bil | |
ARGX
| argenx SE ADR | Cssxywb | Dqmq | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wcgqgcd | Gnq | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gpzmnnq | Wjqzk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Cgnspsx | Lmgrt | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nnyycgsblh | Trrbf | $12.5 Bil | |
INCY
| Incyte Corp | Pnlwddm | Yffrnj | $11.6 Bil |